Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Medy Tox Inc (086900 KS)
Watchlist
56
Analysis
Health Care
•
South Korea
Medy-Tox Inc. is a biopharmaceutical company. The Company researches, develops and manufactures biopharmaceutical products using clostridium botulinum which is a microorganism toxin.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bullish
•
Thematic (Sector/Industry)
•
16 Nov 2017 14:57
KOSDAQ's Bullish Run - Main Drivers & Stocks to Pick
KOSDAQ is getting really hot. Over the past three months, KOSDAQ index climbed 22.89% by 145.31 points from 642.11 on Aug 17 to 780.22 today on Nov...
Sanghyun Park
Follow
699 Views
Share
bullish
•
Samsung Electronics Pref Shares
•
05 Nov 2017 16:54
Samsung Electronics Common-Pref Spread - Data & Situational Study
Let's do one interesting study here. In the last month (Oct 10-Nov 3), Samsung Electronics Pref Shares (005935 KS) ranked fifth in the local...
Sanghyun Park
Follow
403 Views
Share
bullish
•
Thematic (Sector/Industry)
•
05 Oct 2017 14:59
Foreign Investors Vs. Local Institutions in Korean Stock Market - Who Is Right?
Last month, foreign investors went on a buying spree in the Korea's second largest stock market, KOSDAQ. In contrast, they went on a selling spree...
Sanghyun Park
Follow
1.1k Views
Share
bearish
•
Celltrion Healthcare
•
07 Jun 2017 11:23
Celltrion Healthcare IPO Part 1 - Schedule, Financials & Valuation
Celltrion Healthcare (091990 KS), which is Celltrion Inc (068270 KS)’s overseas production distribution (sales) and marketing unit, just submitted...
Sanghyun Park
Follow
784 Views
Share
bullish
•
Thematic (Sector/Industry)
•
01 Mar 2017 02:02
Comprehensive List of Holdco Conversion Candidates in Korea
Holdco (holding company) conversion candidates in Korea have been some of the best performing stocks in Korea in the past six months. In this...
Douglas Kim
Follow
1.2k Views
Share
First
Previous
4
5
6
7
8
9
10
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x